VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma

被引:39
作者
Zhou, Quan [1 ]
Zhu, Yong [2 ]
Deng, Zhansheng [2 ]
Long, Haitao [2 ]
Zhang, Shaoxian [1 ]
Chen, Xingli [1 ]
机构
[1] Xuzhou Med Coll, Huaian Hosp, Dept Orthopaed, Huaian, Peoples R China
[2] Cent S Univ, Xiangya Hosp, Dept Orthopaed, Changsha, Hunan, Peoples R China
来源
SURGICAL ONCOLOGY-OXFORD | 2011年 / 20卷 / 01期
关键词
EMMPRIN; VEGF; Clinical Pathology; Osteosarcoma; Survival; ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASE INDUCER; PROGNOSTIC RELEVANCE; CANCER PROGRESSION; POOR-PROGNOSIS; ANGIOGENESIS; CD147; METASTASIS; INVASION; SARCOMA;
D O I
10.1016/j.suronc.2009.09.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate the clinicopathologic characteristics of Vascular Endothelial Growth Factor (VEGF) and Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) expression in osteosarcoma, and to evaluate the clinical significance of these two markers in the survival of osteosarcoma. Methods: VEGF and EMMPRIN expression in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against VEGF and EMMPRIN. The correlation of VEGF and EMMPRIN expression with the clinicopathologic features and with the survival of osteosarcoma was subsequently assessed. Results: The expression of VEGF and EMMPRIN was detected in 47/65 (72.31%) and 45/65 (69.23%) of patients with osteosarcoma, respectively. Positive expression of VEGF and EMMPRIN was significantly correlated with surgical stage and percentage of dead cells of osteosarcoma. A significant correlation was found between the expression of VEGF and EMMPRIN in osteosarcoma (r = 0.89, p = 0.01). Additionally, surgical stage, percentage of dead cells, VEGF and EMMPRIN expression showed significant influence on overall survival (OS) and disease-free survival (DFS) in univariate analysis. In multivariate analysis, surgical stage (IIA versus IIB/III) and percentage of dead cells (<= 90% versus >90%) were significant for DFS and OS. Those patients with VEGF+/EMMPRIN+ co-expression showed significantly shorter OS and DFS compared with VEGF-/EMMPRIN-expression. Conclusion: According to our study, the overexpression of VEGF or EMMPRIN may be an important feature of osteosarcoma. A combined detection of VEGF/EMMPRIN co-expression may benefit us in prediction of a poor survival of osteosarcoma. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:13 / 19
页数:7
相关论文
共 32 条
  • [1] Asai T, 1998, INT J CANCER, V76, P418, DOI 10.1002/(SICI)1097-0215(19980504)76:3<418::AID-IJC21>3.0.CO
  • [2] 2-5
  • [3] BRIAN I, 2007, CLIN CANCER RES, V13, pS741
  • [4] Chemotherapy resistance in osteosarcoma: current challenges and future directions
    Chou, Alexander J.
    Gorlick, Richard
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (07) : 1075 - 1085
  • [5] ENNEKING WF, 1980, CLIN ORTHOP RELAT R, P106
  • [6] Vascular endothelial growth factor as a target for anticancer therapy
    Ferrara, N
    [J]. ONCOLOGIST, 2004, 9 : 2 - 10
  • [7] Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas - Role in epithelio-stromal interactions and matrix metalloproteinase induction
    Gabison, EE
    Mourah, S
    Steinfels, E
    Yan, L
    Hoang-Xuan, T
    Watsky, MA
    De Wever, B
    Calvo, F
    Mauviel, A
    Menashi, S
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (01) : 209 - 219
  • [8] Deglycosylation of CD147 down-regulates matrix metalloproteinase-11 expression and the adhesive capability of murine hepatocarcinoma cell HcaF in vitro
    Jia, Li
    Zhou, Huimin
    Wang, Shujing
    Cao, Jun
    Wei, Wei
    Zhang, Jianing
    [J]. IUBMB LIFE, 2006, 58 (04) : 209 - 216
  • [9] Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts
    Kanekura, T
    Chen, X
    Kanzaki, T
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (04) : 520 - 528
  • [10] Kaya M, 2000, CLIN CANCER RES, V6, P572